Overview A Phase 1 Dose Escalation Study of IPI-493 Status: Terminated Trial end date: 2011-07-01 Target enrollment: Participant gender: Summary IPI-493 is a potent inhibitor of heat shock protein 90 (Hsp90) and is orally bioavailable via a novel formulation. Phase: Phase 1 Details Lead Sponsor: Infinity Pharmaceuticals, Inc.